Pay Attention to this Trade Activity: TherapeuticsMD, Inc.

TherapeuticsMD, Inc. kicked off the trading day on 08/09/19 with a price increase of 17.42%, equivalent to $0.46 relative change for the day. Taking a more long-term approach, TXMD had a 52-week range of $1.82 to $6.94. At the time of this article’s publishing, this stock is trading at $3.10 after starting the trading session at $2.83. Moving on, the stock has demonstrated a 52-week change amounting to -24.24, alongside an S&P500 52-Week Change of -35.79. At the time of writing, this stock’s 50-day Moving Average stands at $2.52, while the 200-day Moving Average of this stock is currently $4.16.

Currently, this company’s share volume is sitting at $9,713,926, but has maintained average daily volume of $3.68M. This stock has generated an average Year to Date volume of $3.25 million, alongside an average 20-day volume of $3.54 million. This publicly-traded company’s shares outstanding now amounts to $253.17 million, simultaneously with a float of $198.35 million. The organization now has a market capitalization sitting at $784.83 million.

TherapeuticsMD, Inc.(TXMD) Ownership Data

Now let’s turn our focus to how large-scale investors are behaving with this stock. TherapeuticsMD, Inc.’s current insider ownership accounts for 17.76%, in contrast to 80.90% institutional ownership. According to the most recent latest insider trade that took place on May 13 this organization’s Director bought 30,000 at the rate of 3.33, making the entire transaction hit 99,870 in total value, affecting insider ownership by 66,000. Preceding that transaction, on May 13 Company’s Director bought 2,400 at a price of 3.34, making the whole transaction’s value amount to 8,016. This particular insider is now the holder of 685,900 in total.

If we take a glance at the Ownership summary of TherapeuticsMD, Inc.’s stock, 175 Institutional holders make up 80.44% of its total stock ownership. All together, they are the legal holders of 194,046,446 shares, which are valued at about $601,543,983 in total. If we focus on the top 3 stockholders for this publicly-traded organization, BANK OF NEW YORK MELLON CORP owns 24.14 million shares, with PRICE T ROWE ASSOCIATES INC /MD/ in 2nd place owning 22.0 million shares and JPMORGAN CHASE & CO in third place with total ownership of 19.38 million shares.

TherapeuticsMD, Inc. (TXMD) Earnings and Revenue Data

The corporation racked up revenue of $5.09million for the previous financial quarter, compared to the mean analyst estimate of $5.00 million. This company achieved a net margin of -907.71 while generating a return on equity of -154.75. TherapeuticsMD, Inc.’s full-quarter revenue increased by 4.77%, when compared against the year-ago quarter. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.

TherapeuticsMD, Inc.’s EPS decrease for this current 12-month fiscal period is -57.50%, and is forecasted to reach 55.10% in the upcoming year. Looking at the long run, market analysts have predicted that Company’s EPS will increase by 19.50% through the next 5 years, which can be compared against the -21.50% growth it accomplished over the previous five years trading on the market.

Additional Trading Performance Indicators

Now turning our attention to the current performance indicators for TherapeuticsMD, Inc., this organization’s Quick Ratio in the last reported quarter now stands at 3.30. The company has managed to achieve an average true range (ATR) of 0.22. Alongside those, its Beta score is 1.82.

Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 48.15 for this organization. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 12.40, whereas its price to cash per share for the last quarter landed at 0.49.

In the same vein, TXMD’s Diluted EPS (Earnings per Share) trailing twelve month was posted at -0.64, a figure that is expected to reach -0.17 in the next reported quarter, and analysts expect it will be 55.10% at the market close of one year from today’s date.